RxDoctor Payments Data

Charles Bruce-Tagoe, MD

Internal Medicine · Stratford, CTNPI 1417122946

Payments from drug & device makers

$399in general payments, 2019–2025

Across 13 payments — averaging $30.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$131
  • Johnson & Johnson$117
  • Merck$30
  • Lilly USA, LLC$28
  • Pfizer$27
  • Novo Nordisk$21
  • plus $46 from 3 others

What the payments were for

  • Food & beverage$399100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$399 in reported general payments places this provider in the 65th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$65,681
Medicare patients
206
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$129,178
EliquisApixaban92$100,058
JardianceEmpagliflozin83$91,739
JanuviaSitagliptin Phosphate62$71,516
FarxigaDapagliflozin Propanediol60$69,876
LinzessLinaclotide61$44,427
MounjaroTirzepatide32$42,769
XareltoRivaroxaban23$37,510
EntrestoSacubitril/Valsartan17$20,810
MyrbetriqMirabegron34$19,754
TrulicityDulaglutide16$17,549
TradjentaLinagliptin15$17,310
InvokanaCanagliflozin12$16,848
SymbicortBudesonide/Formoterol Fumarate33$7,862
Atorvastatin Calcium709$6,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$129,178102 claims
Boehringer IngelheimJardiance, Tradjenta$18$109,04898 claims
PfizerEliquis$27$100,05892 claims
AstraZenecaFarxiga, Symbicort$13$77,73893 claims
MerckJanuvia$30$71,51662 claims
Lilly USA, LLCMounjaro, Trulicity$28$60,31748 claims
Johnson & JohnsonXarelto, Invokana$117$54,35735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Stratford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →